<DOC>
	<DOCNO>NCT01605760</DOCNO>
	<brief_summary>The safety efficacy specific sublingual immunotherapy house dust mite allergens patient 60 year age allergic rhinitis confirm allergy house dust mites focus stu First , 111 patient , age 60-75 year , allergic rhinitis confirm allergy D. pteronyssinus D. farinae use skin prick test , serum-specific IgE nasal provocation test include . Patients individually randomise group : active placebo use double-blind method . A total 51 subject sublingual allergen-specific immunotherapy ( SLIT ) group ( Staloral 300R , Stallergens , France ) 57 placebo group monitor three year . The patient record diary card whenever use anti-allergic medication .</brief_summary>
	<brief_title>House Dust Mite SLIT Elderly Patients</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Subjects allergic rhinitis fulfil ARIA criterion positive skin prick test ( SPT ) , positive specific immunoglobulin E ( sIgE ) positive nasal provocation test ( NPTs ) Dermatophagoides pteronyssinus ( Der p ) Dermatophagoides farinae ( Der f ) include study Patients follow characteristic exclude : hypersensitivity allergen , nonallergic rhinitis ( especially senile vasomotor rhinitis ) severe nonstable disease ( especially bronchial asthma ) . However , stable coronary disease , diabetes , arterial hypertension wellcontrolled , mild atopic bronchial asthma permit .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>immunotherapy</keyword>
	<keyword>elderly</keyword>
</DOC>